The Institut Bordet Clinical Haematology Department specialises in determining and treating diseases of the blood.
The Institut Bordet is committed to the treatment of these diseases and to offering patients high-quality, individual treatment.
In addition to the traditional approach to blood diseases, the Institut is also engaged in the development of innovative and complex techniques and therapies.
The Institut’s mission covers three main university fields: clinical, research and teaching.
The multidisciplinary nature of the Department, in both its diagnostic and therapeutic approaches, forms an integral part of all decisions concerning the patient.
The expertise of the Clinical Haematology Department includes the treatment of:
- high and low grade lymphoma
- multiple myeloma and associated conditions (POEMS syndrome, amyloidosis, etc)
- acute and chronic leukaemia
- myelodysplastic syndromes, myeloproliferative syndromes (chronic myeloid leukemia, Vaquez disease, essential thrombocytosis, myelofibrosis).
The Department has at its disposal all the modern technology needed to ensure the highest level of care:
- Cell therapy
- Stem cell transplant treatment
- Isolation in sterile facilities for neutropenic patients following chemotherapy or after medulla aplasia of other origin
- Cytapherisis and photopherisis
- Cord blood banks
To provide patients with the most innovative treatments, the department works in collaboration with many international organisations
- Réseau Amylose, fiolmc (France Intergroupe de la Leucémie Myéloide Chronique), European Reference Network, HOVON, SIE (Societa Italiana Ematologica), JACIEOC (Joint Accreditation Committee ISCT-EBMT), GRAAL (Lala Goelams Sakk), LYSA (The Lymphoma Study Association), EHA (European Hematology Association), EBMT (European Society for Blood and Marrow Transplantation), MaRIH (Filière de santé Maladies Rares Immuno-hématologiques) , LOC (Réseau Expert National pour les Lymphome oculo-cérébraux), ifm (intergroupe francophone du myéome), SIH (Société Française d'Hématologie), SFGM (Société Francophone de greffe de moelle et de Thérapie Cellulaire, ISCL (International Society of Cutaneous Lymphomas), GFILC,BHS, EORTC, EuroBloodNet, Amylose AL (Centre de référence Amylose AL et autres maladies par dépôts d'immunoglobulines monoclonales) , ISA (International Society of Amyloidosis), IELSG (INternational Extranodal Lymphoma Study Group)
National and international approvals
- since 2006: Accreditation Joint Accreditation Committee ISCT-Europe & EBMT (JACIE) for haematopoietic stem cell transplants in adults and children
- since 2011: AFMPS approval for the "banking" of haematopoietic stem cells, cord blood and mesenchymal cells.
- since 2012: Accreditation Netcord/FACT for the cord blood bank
- since 2021: Accreditation Joint Accreditation Committee ISCT-Europe & EBMT for cell therapy by “CAR T cells”
The Haematology Department is recognised as:
- A European expert centre for several rare diseases (European Reference Network (ERN) : https://www.ern-rnd.eu/)) :
- Acute promyelocytic leukaemia: Dr Wittnebel / Dr Andreozzi
- Acute lymphoblastic leukaemia: Dr Buntinx / Dr Salaroli
- Amyloidosis: Pr Meuleman / Dr Rizzo / Dr Vercruyssen
- Burkitt lymphoma: Dr Massaro / Pr De Wilde
- T lymphoma: Dr Wolfromm / Dr Maerevoet
- Cutaneous lymphoma: Dr Maerevoet/ Dr Wolfromm / Dr De Vicq
- Mantle cell lymphoma: Pr De Wilde / Dr Massaro
- Cerebral lymphoma: Pr De Wilde / Dr Vercruyssen
- Centre Joint Accreditation Committee ISCT-Europe & EBMT:
- Cell immunotherapy (CAR T cells) : Dr Andreozzi
- Cytapheresis: Dr Salaroli / Dr Dallemagne
- Particular expertise in:
- Allogenic transplants of the haploidentical type: Dr Lewalle / Dr Wittnebel
- Therapeutic photopheresis for Graft Versus Host Disease : Dr Lewalle / Dr Salaroli
- Chronic lymphoid leukaemia for more than 30 years in close cooperation with research laboratories (prognostic and micro-environmental factors, action of new drugs, etc.) and in clinical research (clinical studies, access to new drugs)
- Myeloma and amyloidosis with close cooperation between our clinical and fundamental research units (mesenchymal cell treatment protocol, immunotherapy, etc.)
- Teaching is provided at all levels of training: medical students, BioMed BACH3 students, oncology nurses, EHA Master Classes, GPs, doctors following specialist training, paramedics, the general public.
- All members of the multidisciplinary team are involved on a day-to-day basis in teaching and transmitting our expertise and passion for haematology.
Research projects
Participation of the Hematology Department in research projects with the following laboratories :
EXPERIMENTAL HAEMATOLOGY LABORATORY (HEMEXP)
CLINICAL CELLULAR THERAPY RESEARCH LABORATORY (LTCC)
Project 1
The prognostic value of cognitive function, biomarkers of ageing and clinical factors in elderly patients with malignant haemopathy admitted for chemotherapy (Dominique Bron, MD, PhD)
- Project leader : Dominique Bron
- Collaborations : H. Wildiers, M. Delforge (KUL)
- Funding : Télévie, FNRS, Fonds Yvonne Boël
Project 2
Interculturality and Transplantation
- Project leaders : Sandra Michiels, Patrick Crombez
- Collaboration : MASCC (International, Prof Klastersky)
- Funding : «Association Jules Bordet» / BHS / Fondation Kisane
Project 3
Role of radio-immunotherapy in myeloma
- Project leaders : Nathalie Meuleman, Marie Vercruyssen, Patrick Flamen
- Funding : «Association Jules Bordet»
Project 4
Protocoles de recherche clinique académiques et pharmaceutiques
- Project leaders : Dominique Bron and colleagues
- Funding : Fonds Ariane, Pharma
Our team
- Hematologists
- Pr Nathalie MEULEMAN, Head of Department
- Pr Virginie DE WILDE, Head of Department (associated)
- Dr Fabio ANDREOZZI
- Pr Samantha BENGHIAT
- Dr Sarah BUNTINX
- Dr Martin COLARD
- Dr Julie DALLEMAGNE
- Pr Philippe LEWALLE
- Dr Marie MAEREVOET
- Dr Fulvio MASSARO
- Dr Ornella RIZZO
- Dr Adriano SALAROLI
- Dr Chloé SPILLEBOUDT
- Dr Marie VERCRUYSSEN
- Pr Sebastian WITTNEBEL
- Dr Alice WOLFROMM
- Consultants
- Pr Dominique BRON
- Dr Axelle GILLES
- Dr Françoise LE MOINE
- Pr Serge MOTTE
THE TEAM
- Nurses (health care coordinators) (Bordet)
- Mrs Sophie DELAUNOIS
Myeloma – Autograft
sophie.delaunois@hubruxelles.be
02/541.73.94 - Mrs Marie DUBOIS
Lymphoma – Autograft
marie.dubois@hubruxelles.be
02/555.85.27 - Mrs Jessica PINTO
Lymphoma
jessica.pinto@hubruxelles.be
02/541.38.88 - Mrs Rezarta AJAZI
Allogeneic transplant – Autograft externe center
rezarta.ajazi@hubruxelles.be
02/541.30.22 - Mrs Souad HAJJI
Allogeneic transplant
souad.hajji@hubruxelles.be
02/541.35.16 - Mrs Marie-France JAIVENOIS
Allogeneic transplant
m-f.jaivenois@hubruxelles.be
02/541.33.30
- Mrs Sophie DELAUNOIS
- Hematology Secretary
- 02/555.36.60
- secretariat.hematologie@hubruxelles.be
- Mrs Sabine ACKERMANS
- Mrs Déborah BREWEE
- Consultations Secretary
- 02/541.36.84
- Mrs Yasemin BAYRAKTAR
- Mrs Jennifer MARINUS
- Dayhospital
- 02/541.33.78
- 02/541.33.78
- Hospitalisation
- Unit B13 : 02/541.33.54 or 02/541.33.55
- Unit B14 : 02/555.37.26
- Apheresis Unit
- Tel : +32 (0)2 541 32 11 (ou 74)
- Dr Adriano Salaroli - Head
- Mevr. Maryline Horvath - Sekretary
- Clinical Research Cell
- Mrs Lina ADU POKU
lina.adupoku@hubruxelles.be
02/541.39.11 - Mrs Aude BOVENKAMP
aude.bovenkamp@hubruxelles.be
02/541.72.05 - Mrs Elizabeth GARFORTH
elizabeth.garforth@hubruxelles.be
02/555.42.39 - Mrs Marie DE CLIPPELE
marie.declippele@hubruxelles.be
02/541.32.92 - Mrs Brandy TROISFONTAINE
brandy.troisfontaine@hubruxelles.be
02/541.33.57 - Mrs Bénédicte VUCIC
benedicte.vucic@hubruxelles.be
02/541.36.47
- Mrs Lina ADU POKU
- Quality Unit
- Mrs Aurélie TIMMERMANS
02/541.72.25 - Mrs Célia MEURILLON
02/541.37.26
- Mrs Aurélie TIMMERMANS
- Transplant Coordination Unit
- 02/541.32.12
- Mrs Anne DE MEUTER (Data Manager EBMT)
- Mrs Sandra MICHIELS (Coordinatrice)
- Mr Redouane ROUAS (Suppléant)
25/04/2023
Scientific publications
Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.
Authors : Depoorter V, Vanschoenbeek K, Decoster L, De Schutter H, Debruyne PR, De Groof I, Bron D, Cornélis F, Luce S, Focan C, Verschaeve V, Debugne G, Langenaeken C, Van den Bulck H, Goeminne JC, Teurfs W, Jerusalem G, Schrijvers D, Petit B, Rasschaert M, Praet JP, Vandenborre K, Milisen K, Flamaing J, Kenis C, Verdoodt F, Wildiers H
Year : 2023
Journal : J Geriatr Oncol
Pages : 101428
Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Natural Nanocarriers: Concise Review.
Authors : Draguet F, Bouland C, Dubois N, Bron D, Meuleman N, Stamatopoulos B, Lagneaux L
Year : 2023
Journal : Pharmaceutics
Volume : 15
Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.
Authors : Massaro F, Meuleman N, Bron D, Vercruyssen M, Maerevoet M
Year : 2022
Journal : Cancers (Basel)
Volume : 14
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
Authors : Zijlstra JM, Follows G, Casasnovas RO, Vermaat JSP, Kalakonda N, Choquet S, Hill B, Thieblemont C, Cavallo F, Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vassilakopoulos TP, Samal P, Ku M, Xu J, Corona K, Chamoun K, Shah J, Canales M, Maerevoet M
Year : 2022
Journal : Cancers (Basel)
Volume : 14
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.
Authors : Andreozzi F, Massaro F, Wittnebel S, Spilleboudt C, Lewalle P, Salaroli A
Year : 2022
Journal : Int J Mol Sci
Volume : 23